A breakthrough at the University of Saskatchewan could potentially streamline the calving season for beef producers. The university’s research has shown that Cetrorelix, a hormone drug commonly used in human IVF treatments, could soon be utilized in the cattle industry. Dr. Jaswant Singh, along with graduate students Dylan Farmer and Carlos Leonardi, discovered the drug’s effectiveness in inducing ovulation synchronization in cows, leading to simultaneous pregnancies and, ultimately, synchronized calving.
Dr. Singh explained that by reducing the calving period from two months to one month using Cetrorelix, labor costs could be minimized, and animal management could be optimized. This innovation could result in higher weaning weights for calves, ultimately increasing profits for farmers. Garner Deobald, a beef rancher and marketing manager at BoviGen Genetic Services, expressed enthusiasm for integrating Cetrorelix into their breeding practices, anticipating potential benefits in enhancing genetic selection and calf predictability.
The possibility of Cetrorelix making artificial insemination a more attractive breeding method is also being explored. This advancement could lead to improved genetic management within herds and provide more accurate information on calf traits. The University of Saskatchewan has applied for a patent on Cetrorelix and is collaborating with pharmaceutical companies to bring the drug to market. Dr. Singh is hopeful that this innovation will not only benefit local farmers but also have global implications, making artificial insemination more widely adopted in the industry.
Overall, the prospects for Cetrorelix in cattle breeding appear promising, with most regulatory requirements already met, signaling a potential shift in breeding practices towards more efficient and cost-effective methods.